J Cancer 2023; 14(5):850-873. doi:10.7150/jca.81899 This issue Cite

Review

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Yuanfeng Zhang1, Juanjuan Wu2*, Chaobin Zhao1*, Shuyuan Zhang1, Jianbo Zhu2✉

1. Binzhou Medical University, Yantai, Shandong, 264003, China
2. Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, Shandong, 256600, China
* These authors contributed equally.

Citation:
Zhang Y, Wu J, Zhao C, Zhang S, Zhu J. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. J Cancer 2023; 14(5):850-873. doi:10.7150/jca.81899. https://www.jcancer.org/v14p0850.htm
Other styles

File import instruction

Abstract

Graphic abstract

Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma membrane, the surface of secreted cellular exosomes, in cell nuclei, or as a circulating soluble protein. This interaction can lead to immune escape in cancer patients. In clinical settings, PD-L1 plays an important role in tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. PD-L1 inhibitors are also essential components of tumor immunotherapy. Thus, the detection of PD-L1 levels is crucial, especially in the era of precision cancer therapy. In recent years, innovations have been made in traditional immunoassay methods and the development of new immunoassays for PD-L1 detection. This review aims to summarize recent research progress in tumor PD-L1 detection technology and highlight the clinical applications of PD-L1.

Keywords: programmed death-1, programmed death-ligand 1, immunoassay, immunosuppressant, tumor, precision cancer therapy.


Citation styles

APA
Zhang, Y., Wu, J., Zhao, C., Zhang, S., Zhu, J. (2023). Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. Journal of Cancer, 14(5), 850-873. https://doi.org/10.7150/jca.81899.

ACS
Zhang, Y.; Wu, J.; Zhao, C.; Zhang, S.; Zhu, J. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. J. Cancer 2023, 14 (5), 850-873. DOI: 10.7150/jca.81899.

NLM
Zhang Y, Wu J, Zhao C, Zhang S, Zhu J. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. J Cancer 2023; 14(5):850-873. doi:10.7150/jca.81899. https://www.jcancer.org/v14p0850.htm

CSE
Zhang Y, Wu J, Zhao C, Zhang S, Zhu J. 2023. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. J Cancer. 14(5):850-873.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image